Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : VS-01
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : HealthCare Royalty
Deal Size : $201.7 million
Deal Type : Financing
Genfit Completes Royalty Financing with HCRx & Repurchase Offer Results
Details : The financing aims to advance the company's product pipeline including VS-01, an investigational drug based on a proprietary scavenging liposomal technology. It is treated in patients with ACLF.
Product Name : VS-01
Product Type : Other Small Molecule
Upfront Cash : $141.2 million
March 20, 2025
Lead Product(s) : VS-01
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : HealthCare Royalty
Deal Size : $201.7 million
Deal Type : Financing
Lead Product(s) : VS-01
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : HealthCare Royalty
Deal Size : $189.5 million
Deal Type : Financing
GENFIT Announces Royalty Financing, Debt Overhang Resolution Plan
Details : The company will use the proceeds to develop its pipeline focused on Acute-on-Chronic Liver Failure (ACLF), including VS-01, a first-in-class innovative liposomal-based therapeutic product.
Product Name : VS-01
Product Type : Other Small Molecule
Upfront Cash : $133.2 million
January 30, 2025
Lead Product(s) : VS-01
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : HealthCare Royalty
Deal Size : $189.5 million
Deal Type : Financing
Lead Product(s) : Ezurpimtrostat
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Grants GENFIT’s GNS561 Orphan Drug Designation for the Treatment of Cholangiocarcinoma
Details : GNS561 (ezurpimtrostat) is a PPT-1 (Palmitoyl Protein Thioesterase-1) inhibitor that blocks autophagy. Autophagy is activated in tumor cells in response to certain conditions, due to a tumor cell growth in advanced cancers.
Product Name : GNS561
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 13, 2022
Lead Product(s) : Ezurpimtrostat
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ezurpimtrostat
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : GenScience Pharmaceuticals
Deal Size : $3.4 million
Deal Type : Acquisition
On heels of Global Strategic Partnership Announced Today, GENFIT Acquires Rights to Novel Asset
Details : Through the acquisition of exclusive rights from Genoscience Pharma to develop and commercialize the investigational treatment GNS561 in cholangiocarcinoma in the United States, Canada and Europe, including the United Kingdom and Switzerland.
Product Name : GNS561
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 17, 2021
Lead Product(s) : Ezurpimtrostat
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : GenScience Pharmaceuticals
Deal Size : $3.4 million
Deal Type : Acquisition
Lead Product(s) : Elafibranor
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase III
Sponsor : Ipsen
Deal Size : $583.0 million
Deal Type : Licensing Agreement
Details : The agreement gives Ipsen exclusive worldwide* license to develop, manufacture and commercialize GENFIT’s GFT505, an investigational treatment elafibranor, for people living with Primary Biliary Cholangitis (PBC).
Product Name : GFT505
Product Type : Other Small Molecule
Upfront Cash : $137.7 million
December 17, 2021
Lead Product(s) : Elafibranor
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase III
Sponsor : Ipsen
Deal Size : $583.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Nitazoxanide
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GENFIT Provides Pipeline Update and Launch of New Clinical Programs
Details : GENFIT is launching a clinical program with nitazoxanide (NTZ) in this disease. A Phase 1 study to evaluate pharmacokinetics and pharmacodynamics in patients with varying degrees of hepatic impairment is expected to start in 4Q21 with clinical data expec...
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 05, 2021
Lead Product(s) : Nitazoxanide
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Elafibranor
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Company presents Elafibranor, dual agonism of peroxisome proliferator-activated alpha/delta receptors found to be efficacious in the treatment of PBC, a rare liver disease.
Product Name : GFT505
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 11, 2021
Lead Product(s) : Elafibranor
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Elafibranor
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Genfit Delivers Latest NASH Drug Failure
Details : Elafibranor did not demonstrate a statistically significant effect on the primary endpoint of NASH resolution without worsening of fibrosis.
Product Name : GFT505
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 05, 2020
Lead Product(s) : Elafibranor
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Elafibranor
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GENFIT Announces First Patient First Visit for ELATIVE Phase 3 Study Evaluating Elafibranor in PBC
Details : ELATIVE™ is a randomized, double blind, placebo-controlled, global multicenter Phase 3 study evaluating the efficacy and safety of elafibranor, a dual PPAR alpha and delta agonist, in PBC.
Product Name : GFT505
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 24, 2020
Lead Product(s) : Elafibranor
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Elafibranor
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Genfit says Covid-19 may not significantly delay NASH trial readout
Details : Company does not expect any significant delay in the interim data readout of its Phase III RESOLVE-IT clinical trial of elafibranor in non-alcoholic steatohepatitis with fibrosis.
Product Name : GFT505
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 04, 2020
Lead Product(s) : Elafibranor
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable